Premium
Review article: Bone biopsy in chronic kidney disease: Patient level end‐point or just another test?
Author(s) -
JORGETTI VANDA
Publication year - 2009
Publication title -
nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 61
eISSN - 1440-1797
pISSN - 1320-5358
DOI - 10.1111/j.1440-1797.2009.01148.x
Subject(s) - medicine , renal osteodystrophy , bone remodeling , bone biopsy , parathyroid hormone , kidney disease , biopsy , chronic kidney disease mineral and bone disorder , calcitriol , bone disease , urology , pathology , endocrinology , vitamin d and neurology , osteoporosis , calcium
SUMMARY The reduction of renal function in chronic kidney disease leads to disturbed calcium and phosphorus metabolism, impaired action of calcitriol, increased parathyroid hormone, FGF‐23 levels and ultimately bone disorders. These disturbances have been traditionally termed renal osteodystrophy, which evaluation and diagnosis require a bone biopsy. In the last four decades, researchers from different countries have developed new techniques and have introduced concepts that allowed the development of bone histomorphometry, considered the key tool to study bone metabolism, remodelling and structure. In this review we focus on the relevance of bone biopsy and its respective histomorphometric analysis to help nephrologists to evaluate patients with chronic kidney disease.